| Lisa Carey |
Lisa Carey is currently the Vice President-Clinical Operations at aTyr Pharma, Inc. She started this position in 2023. Previously, she worked as a Project Manager-Asthma at MURO Pharmaceutical, Inc. from 1995 to 1997. Ms. Carey completed her undergraduate degree at Saint Joseph's College (Maine). |
| Leslie Nangle |
Leslie Nangle is currently working as the Vice President-Research at aTyr Pharma, Inc. Prior to this, Leslie obtained a doctorate degree from The Scripps Research Institute and an undergraduate degree from the University of California, Santa Barbara. |
| Jill M. Broadfoot |
Jill M. Broadfoot currently works at Talphera, Inc., as Independent Director from 2021, Angiocrine Bioscience, Inc., as Director, and aTyr Pharma, Inc., as Chief Financial Officer from 2018. Ms. Broadfoot also formerly worked at Otonomy, Inc., as Independent Director from 2021 to 2023, Medical Imaging Centers of America, Inc., as Divisional Controller in 1994, Vical, Inc., as Chief Financial Officer, Secretary & Senior VP from 2004 to 2013, DJO Global, Inc., as Vice President-Finance & Controller in 2004, Ernst & Young LLP, as Audit Manager from 1994 to 1999, GW Pharmaceuticals Ltd., as Vice President & Controller from 2016 to 2017, Emerald Health Pharmaceuticals, Inc., as Chief Financial Officer from 2017 to 2018, and Emerald Health Bioceuticals, Inc., as Chief Financial Officer from 2017 to 2018. Ms. Broadfoot received her undergraduate degree in 1993 from San Diego State University. |
| John K. Clarke |
Mr. John K. Clarke is an Independent Director at aTyr Pharma, Inc. and a Managing Partner at CHP Management, Inc. He is on the Board of Directors at aTyr Pharma, Inc., Cureatr, Inc., Ivenix, Inc. and Hands Together. Mr. Clarke was previously employed as an Independent Director by Verastem, Inc., an Independent Director by Alnylam Pharmaceuticals, Inc., an Independent Director by Momenta Pharmaceuticals, Inc., a Chairman by Cubist Pharmaceuticals LLC, a General Partner by DSV Partners IV LP, a Chief Executive Officer by Alkermes, Inc., a Chief Executive Officer by Arris Pharmaceuticals Corp., a Chief Executive Officer by Axys Pharmaceuticals, Inc., a Chief Executive Officer by DNX Corp., a Principal by GE Aerospace, and a Chairman & President by Greater Philadelphia Venture Group. He also served on the board at Vividion Therapeutics, Inc., Abide Therapeutics, Inc., Sirtris Pharmaceuticals, Inc., VISICU, Inc., Melinta Subsidiary Corp., National Venture Capital Association, Philadelphia Industrial Development Corp., Prealize Health, Inc. /California/, Rib X Pharmaceuticals, Inc., Techrx Technology Services Corp., TechRx, Inc. and The Jackson Laboratory. He received his undergraduate degree from Harvard University and an MBA from The Wharton School of the University of Pennsylvania. |
| Timothy P. Coughlin |
Mr. Timothy P. Coughlin, CPA, is a Chairman at aTyr Pharma, Inc., an Independent Director at Travere Therapeutics, Inc. and an Independent Director at Fate Therapeutics, Inc. He is on the Board of Directors at Travere Therapeutics, Inc. and Fate Therapeutics, Inc. Mr. Coughlin was previously employed as a Chief Financial Officer by Neurocrine Biosciences, Inc., a Vice President-Financial Services by Catholic Health Initiatives, a Vice President-Financial Services by CommonSpirit Health (Illinois), and a Senior Manager-Health Sciences Practice by Ernst & Young LLP. He also served on the board at Peloton Therapeutics, Inc. He received his undergraduate degree from Temple University (Pennsylvania) and a graduate degree from San Diego State University. |
| Sanjay S. Shukla |
Dr. Sanjay S. Shukla, MD, is a President, Chief Executive Officer & Director at aTyr Pharma, Inc. He is on the Board of Directors at aTyr Pharma, Inc. Dr. Shukla was previously employed as a Vice President & Head-Integrated Medical Services by Novartis AG and a Chief Executive Officer by Rxmd, Inc. He received his undergraduate degree from the University of Maryland, a graduate degree from the University of Maryland and a doctorate degree from Howard University College of Medicine. |
| Svetlana Lucas |
Dr. Svetlana Lucas is an Independent Director at aTyr Pharma, Inc. and a Chief Business Officer at Scribe Therapeutics, Inc. She is on the Board of Directors at aTyr Pharma, Inc. Dr. Lucas was previously employed as a Senior Vice President-Business Development by Tizona Therapeutics, Inc. and a Head-Oncology & Inflammation by Amgen, Inc. She received her undergraduate degree from Moscow State University Lomonosov and a doctorate degree from California Institute of Technology. |
| Jane A. Gross |
Dr. Jane A. Gross is an Independent Director at BriaCell Therapeutics Corp., an Independent Director at aTyr Pharma, Inc. and an Independent Director at BriaPro Therapeutics Corp. She is on the Board of Directors at BriaCell Therapeutics Corp., aTyr Pharma, Inc., Washington Biotechnology & Biomedical Association and BriaPro Therapeutics Corp. Dr. Gross was previously employed as a Chief Scientific Officer & Senior Vice President by Aptevo Therapeutics, Inc., a VP-Applied Research & Non-Clinical Development by Emergent BioSolutions, Inc., and a Vice President-Immunology Research by ZymoGenetics, Inc. She received her doctorate degree from the University of California, Berkeley. |
| Paul R. Schimmel |
Dr. Paul R. Schimmel is an Independent Director at aTyr Pharma, Inc., a Professor at The Scripps Research Institute, an Advisor at Longwood Fund Management LLC, a Member at American Academy of Arts & Sciences, a Member at American Philosophical Society, a Member at National Academy of Inventors, a Member at National Academy of Medicine, a Member at National Academy of Medicine (United States), a Member at National Academy of Sciences, a Professor at Skaggs Institute For Chemical Biology and a Venture Partner at CHP Management, Inc. He is on the Board of Directors at Abide Therapeutics, Inc., aTyr Pharma, Inc., KinDex Pharmaceuticals, Inc., Reactive Biosciences, Inc. and Tevard Biosciences, Inc. Dr. Schimmel was previously employed as an Independent Director by Tocagen, Inc., an Independent Director by Alnylam Pharmaceuticals, Inc., a Co-Founder by Metabolon, Inc., a Co-Founder by Alkermes, Inc., a Co-Chairman by Repligen Corp., a Chairman-Biological Chemistry Division by American Chemical Society, a Co-Founder by Cubist Pharmaceuticals LLC, a Member-Scientific Advisory Board by Illumina, Inc., and a Professor by Massachusetts Institute of Technology. He also served on the board at Sirtris Pharmaceuticals, Inc., Momenta Pharmaceuticals, Inc., Alkermes Plc, Avicena Group, Inc. and Vividion Therapeutics, Inc. He received his undergraduate degree from Ohio Wesleyan University, a doctorate degree from Massachusetts Institute of Technology and a doctorate degree from Cornell University. |
| Sara L. Zaknoen |
Dr. Sara L. Zaknoen, MD, is an Independent Director at aTyr Pharma, Inc. She is on the Board of Directors at aTyr Pharma, Inc. Dr. Zaknoen was previously employed as a Chief Medical Officer by Ignyta, Inc., a Chief Medical Officer by Tragara Pharmaceuticals, Inc., a Director-Clinical Oncology Research by Schering-Plough Research Institute, a Chief Medical Officer by Cabrellis Pharmaceuticals Corp., an Executive Director-Clinical Oncology Research by Novartis Pharmaceuticals Corp., a Chief Medical Officer by Polynoma LLC, a Director-Experimental Therapeutics by The Western Pennsylvania Hospital, and a Medical Director by University of Cincinnati (Ohio). She received her undergraduate degree from Valparaiso University and a doctorate degree from Indiana University. |
